TWO · 6696.TWO
Lin BioScience, Inc.
NT$159.00-NT$2.50 (-1.55%)
Lin BioScience, Inc.’s quoted price sits in the upper half of its reported 52-week range, 23.19% below the high.
Loading market information…
TWO · 6945.TWO · TWD
Stock price
Quote as of Oct 30, 2026, 05:30 AM UTC. Cached market data; not a live quote.
One-year closing-price history · TWD. Historical prices are not a forecast.
AP Biosciences Inc’s quoted price sits in the lower half of its reported 52-week range, 43.43% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE COMPANY BEHIND THE TICKER
AP Biosciences Inc. is a pioneering clinical-stage biopharmaceutical company dedicated to the research and development of bispecific antibody drugs, aiming to fulfill critical unmet medical needs. Its robust pipeline features several promising candidates: Leading the pack, IBI302 is in Phase III clinical trials for the treatment of neovascular age-related macular degeneration (nAMD). Further along, AP505 is undergoing Phase I clinical trials for various solid tumors. AP203, also in Phase I, is being investigated for non-small cell lung cancer, head and neck squamous cell carcinoma, and esophageal squamous cell carcinomas. In earlier development, AP402 is currently in the pre-clinical research phase, focusing on breast cancer patients. Additionally, AP601 is also in pre-clinical research, targeting a broader spectrum of malignancies including lung cancer, pancreatic cancer, bladder cancer, ovarian cancer, and other solid tumors. Founded in 2013, the company maintains its headquarters in Taipei City, Taiwan.
Latest available per-share figures in TWD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 08:43 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
NT$159.00-NT$2.50 (-1.55%)
Lin BioScience, Inc.’s quoted price sits in the upper half of its reported 52-week range, 23.19% below the high.
NT$107.00-NT$5.50 (-4.89%)
Gongwin Biopharm Holdings Co., Ltd.’s quoted price sits in the upper half of its reported 52-week range, 28.19% below the high.
NT$68.40-NT$2.40 (-3.39%)
Lumosa Therapeutics Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 70.0% below the high.
NT$58.20+NT$1.50 (+2.65%)
PharmaEngine, Inc.’s quoted price sits in the lower half of its reported 52-week range, 21.77% below the high.
NT$64.30-NT$1.40 (-2.13%)
AnnJi’s quoted price sits in the upper half of its reported 52-week range, 25.23% below the high.
NT$45.40-NT$3.10 (-6.39%)
OBI Pharma, Inc.’s quoted price sits in the upper half of its reported 52-week range, 32.04% below the high.
NT$8.37-NT$0.31 (-3.57%)
TaiGen Biopharmaceuticals Holdings Limited’s quoted price sits in the lower half of its reported 52-week range, 48.96% below the high.
NT$33.20-NT$0.60 (-1.78%)
Medigen Biotechnology Corp.’s quoted price sits in the lower half of its reported 52-week range, 23.85% below the high.
